Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction

被引：96

作者：

Hardcastle, IR

Ahmed, SU

Atkins, H

Calvert, AH

Curtin, NJ

Farnie, G

Golding, BT

Griffin, RJ

Guyenne, S

Hutton, C

Källbad, P

Kemp, SJ

Kitching, MS

Newell, DR

Norbedo, S

Northen, JS

Reid, RJ

Saravanan, K

Willems, HMG

Lunec, J

机构：

[1] Univ Newcastle Upon Tyne, Sch Nat Sci Chem, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[2] Univ Newcastle Upon Tyne, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

[3] De Novo Pharmaceut, Cambridge CB4 9ZR, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 05期

基金：

英国工程与自然科学研究理事会; 英国生物技术与生命科学研究理事会;

关键词：

cancer; MDM2; p53; protein-protein interactions;

D O I：

10.1016/j.bmcl.2004.12.061

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of 2-N-alkyl-3-aryl-3-alkoxyisoindolinones has been synthesised and evaluated as inhibitors of the MDM2-p53 interaction. The most potent compound, 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one (NU8231), exhibited an IC50 of 5.3 +/- 0.9 mu M in an ELISA assay, and induced p53-dependent gene transcription in a dose-dependent manner, in the SJSA human sarcoma cell line. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：1515 / 1520

页数：6

共 19 条

[1] Bottger V, 1996, ONCOGENE, V13, P2141
[2] Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy
Chène, P
[J]. NATURE REVIEWS CANCER, 2003, 3 (02) : 102 - 109
[3] Isolation and structure elucidation of chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.
Duncan, SJ
Grüschow, S
Williams, DH
McNicholas, C
Purewal, R
Hajek, M
Gerlitz, M
Martin, S
Wrigley, SK
Moore, M
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (04) : 554 - 560
[4] NMR structure of a complex between MDM2 and a small molecule inhibitor
Fry, DC
Emerson, SD
Palme, S
Vu, BT
Liu, CM
Podlaski, F
[J]. JOURNAL OF BIOMOLECULAR NMR, 2004, 30 (02) : 163 - 173
[5] Mdm2 association with p53 targets its ubiquitination
Fuchs, SY
Adler, V
Buschmann, T
Wu, XW
Ronai, Z
[J]. ONCOGENE, 1998, 17 (19) : 2543 - 2547
[6] Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53
García-Echeverría, C
Chène, P
Blommers, MJJ
Furet, P
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (17) : 3205 - 3208
[7] Development and validation of a genetic algorithm for flexible docking
Jones, G
Willett, P
Glen, RC
Leach, AR
Taylor, R
[J]. JOURNAL OF MOLECULAR BIOLOGY, 1997, 267 (03) : 727 - 748
[8] Assessment of multiple binding modes in ligand-protein docking
Källblad, P
Mancera, RL
Todorov, NP
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (13) : 3334 - 3337
[9] Kitching MS, 1999, SYNLETT, P997
[10] Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
Kussie, PH
Gorina, S
Marechal, V
Elenbaas, B
Moreau, J
Levine, AJ
Pavletich, NP
[J]. SCIENCE, 1996, 274 (5289) : 948 - 953

← 1 2 →